Marciano Joelle
Créteil, Creteil, 94000, France
NCT Number: NCT03035461
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population of the industrialized world. AMD is a progressive degenerative disease affecting the central area of the retina, responsible for distinct vision. Vision loss arises from aberrant new vessel growth which causes the accumulation of blood or fluid within the retina's thickness and eventually leads to permanent scarring. The two major forms of AMD are exudative, or neovascular or "wet", and non-exudative, or "dry".
Vascular endothelial growth factor (VEGF) represents the key modulator of the angiogenetic process and is involved in the pathophysiology of AMD. Anti VEGF therapies are used to treat wet-AMD.
After diagnosis and explanations of the practionner, the patients and their close relatives have still frequently many questions about the intravitreal injections, the prognosis, the risk of visual impairment, etc. Few teams have studied the modalities of diagnosis announcement and the understanding of the patients on the disease course.
The aim of this study is to evaluate the feelings after the AMD diagnosis announcement as well as the understanding of the possibilities of treatment and the clinical surveillance.
Looking for future studies?
Notify Me55 year and older
All sexes
Observational
Créteil, Creteil, 94000, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 1 month after diagnosis
A questionnaire with a list of different feelings: anxiety, distress, relief, resigned, guilty, etc. is proposed to the patient after AMD diagnosis. they can also explain their feelings by themselves.
Time frame: up to 1 month after diagnosis
the patient will score their satisfaction on a numeric scale from 0 (not satisfied at all) to 10 (extremely satisfied)
Time frame: up to 1 month after diagnosis
Time frame: up to 1 month after diagnosis
Time frame: between 6 months and 1 year of follow-up
Time frame: up to 1 month after diagnosis
Time frame: between 6 months and 1 year of follow-up
Time frame: between 6 months and 1 year of follow-up
Time frame: between 6 months and 1 year of follow-up
Time frame: between 6 months and 1 year of follow-up
Centre Hospitalier Intercommunal Creteil
Other
Ressenti du Patient au Moment de l'Annonce du Diagnostic de DMLA
Acronym: PANDA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02725762
Age Related Macular Degeneration, Eye Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT03076697
Age Related Macular Degeneration, Cardiovascular Diseases
View Trial DetailsNCT07318428
Age Related Macular Degeneration, Cardiovascular Diseases
Busan, South Korea
View Trial DetailsNCT07424235
AMD, Age Related Macular Degeneration
View Trial Details